Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BeyondSpring Inc.    BYSI   KYG108301006

BEYONDSPRING INC.

(BYSI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/04/2020 08/05/2020 08/06/2020 08/07/2020 08/10/2020 Date
11.84(c) 12.06(c) 11.66(c) 11.49(c) 11.01(c) Last
78 923 70 438 55 239 51 798 104 631 Volume
+4.50% +1.86% -3.32% -1.46% -4.18% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -71,9 M - -
Net Debt 2020 - - -
P/E ratio 2020 -4,49x
Yield 2020 -
Sales 2021 18,2 M - -
Net income 2021 -104 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,87x
Yield 2021 -
Capitalization 331 M 331 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 18,2x
Nbr of Employees 61
Free-Float 11,5%
More Financials
Company
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology cancer therapies. The Company’s lead product Plinabulin, is being studied in late-stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company's product, Plinabulin, is a marine-derived... 
More about the company
Surperformance© ratings of BeyondSpring Inc.
Trading Rating : Investor Rating : -
More Ratings
Latest news on BEYONDSPRING INC.
06/30New Stem Cell-Based Application for BeyondSpring's Plinabulin Presented at IS..
GL
06/25BEYONDSPRING : 2020 First Quarter Financial Report
PU
06/23New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Comb..
GL
06/19BeyondSpring Announces Pricing of Ordinary Shares
GL
06/18BeyondSpring Announces Proposed Public Offering of Ordinary Shares
GL
06/11BeyondSpring Reports First-Quarter 2020 Financial Results and Operational Upd..
GL
06/09BeyondSpring's PROTECTIVE-2 (Study 106) Phase 2 Trial for Chemotherapy-Induce..
GL
06/03BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plin..
GL
06/02BeyondSpring E-Poster Presented at 2020 ASCO Virtual Scientific Program
GL
05/20BEYONDSPRING INC. : quaterly earnings release
05/13BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemother..
GL
04/30BEYONDSPRING : Study 106 Phase 2 Summary
PU
04/30BeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and ..
GL
04/29CORRECTION – FDA Submission to Change the Primary Endpoint into an Indu..
GL
04/29FDA Submission to Change the Primary Endpoint into an Industry First and Robu..
GL
More news
News in other languages on BEYONDSPRING INC.
06/30New Stem Cell-Based Application for BeyondSpring's Plinabulin Presented at IS..
06/25BEYONDSPRING : 2020 First Quarter Financial Report
06/23New Preclinical Data Demonstrates Immune-Enhancing Effects of Triple I/O Comb..
06/19BeyondSpring Announces Pricing of Ordinary Shares
06/18BeyondSpring Announces Proposed Public Offering of Ordinary Shares
More news
Chart BEYONDSPRING INC.
Duration : Period :
BeyondSpring Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEYONDSPRING INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 42,50 $
Last Close Price 11,01 $
Spread / Highest target 318%
Spread / Average Target 286%
Spread / Lowest Target 254%
EPS Revisions
Managers
NameTitle
Lan Huang Chairman & Chief Executive Officer
Richard J. Daly Chief Operating Officer
Dong Heng Liu Chief Financial Officer
Ramon W. Mohanlal Director & Chief Medical Officer
James Tonra Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
BEYONDSPRING INC.-28.97%331
GILEAD SCIENCES, INC.5.43%86 946
VERTEX PHARMACEUTICALS22.74%71 105
REGENERON PHARMACEUTICALS61.99%65 265
WUXI APPTEC CO., LTD.72.04%38 070
GENMAB A/S55.18%23 785